Zobrazeno 1 - 10
of 116
pro vyhledávání: '"P N, Lara"'
Autor:
Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective i
Externí odkaz:
https://doaj.org/article/f27c30f1bd8e406580492b76ee1bb216
Publikováno v:
ESPOCH Congresses, Vol 3, Iss 1, Pp 298-311 (2023)
Abstract The present research determined the high diversity and structure of the lowland evergreen forest of the Amazon in a locality (Rey de los Andes) of Cuyabeno city, since there is no updated information on this important biome. The linear trans
Externí odkaz:
https://doaj.org/article/c4aac260ca25451b84ff87f8a66dd647
Autor:
Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong-Wu Chen, Huichang Bi, Ai-Ming Yu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 10, Pp 4273-4290 (2023)
During the development of therapeutic microRNAs (miRNAs or miRs), it is essential to define their pharmacological actions. Rather, miRNA research and therapy mainly use miRNA mimics synthesized in vitro. After experimental screening of unique recombi
Externí odkaz:
https://doaj.org/article/f4d6176f67c746b9918b7333fa7e1e5b
Autor:
Diego Abreu, Gustavo Carvalhal, Guillermo Gueglio, Ignacio Tobia, Patricio Garcia, Alvaro Zuñiga, Luis Meza, Rubén Bengió, Carlos Scorticati, Ricardo Castillejos, Francisco Rodriguez, Ana María Autran, Carmen Gonzales, Jose Gadu, Alejandro Nolazco, Carlos Ameri, Hamilton Zampolli, Raúl Langenhin, Diego Muguruza, Marcos Tobías Machado, Pablo Mingote, Juan Yandian, Jorge Clavijo, Lucas Nogueira, Omar Clark, Fernando Secin, Agustín Rovegno, Ana Vilas, Enrique Barrios, Ricardo Decia, Gustavo Guimarães, Sidney Glina, Sumanta K. Pal, Oscar Rodriguez, Joan Palou, Philippe Spiess, Primo N. Lara, W. Marston Linehan, Antonio Luigi Pastore, Stenio C. Zequi
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 671-685 (2021)
PURPOSETo assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries.PATIENTS AND METHODSOf 4,060 patients with renal
Externí odkaz:
https://doaj.org/article/c8a760862ef940b5b22a76bac36c636f
Autor:
Ceila M S Malaque, Christina T G Novaes, Roberta O Piorelli, Jose Y Risk, Jefferson C Murad, Amanda N Lara, Cristiana C Virgulino, Karina T Miyaji, Marcelo L Santoro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 10, p e0010842 (2022)
BackgroundSpiders of the genus Loxosceles are distributed throughout tropical and temperate regions worldwide. Loxosceles spp. bites may evolve to necrosis, with or without intravascular hemolysis. There is no consensus regarding the best treatment t
Externí odkaz:
https://doaj.org/article/53fe574269d14211b2b6fa318f79a65b
Publikováno v:
ESPOCH Congresses, Vol 1, Iss 4, Pp 1155-1165 (2021)
Abstract The present investigation proposes to determine the form factor of the species Eucalyptus saligna in a commercial forest plantation of the Tambillo bajo sector, of the Colta canton, Chimborazo province. For this purpose, 100 individual speci
Externí odkaz:
https://doaj.org/article/138720137ef24570bc3d71af52e99adf
Autor:
Juanita Elizabeth Quino, Fabian Perez, Angelica Perez, April Pangia Vang, Leonie Avendano, Julie Dang, Moon S. Chen, Alexa Morales Arana, Sienna Rocha, Miriam Nuno, Primo N. Lara, Laura Fejerman, Luis G. Carvajal-Carmona
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCancer is the leading cause of death among Latinos, the largest minority population in the United States (US). To address cancer challenges experienced by Latinos, we conducted a catchment area population assessment (CAPA) using validated q
Externí odkaz:
https://doaj.org/article/0b5af534bb644fdbab9a58bd7ae9232b
Autor:
Mamta Parikh, Chengfei Liu, Chun-Yi Wu, Christopher P. Evans, Marc Dall’Era, Daniel Robles, Primo N. Lara, Neeraj Agarwal, Allen C. Gao, Chong-Xian Pan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Niclosamide has preclinical activity against a wide range of cancers. In prostate cancer, it inhibits androgen receptor variant 7 and synergizes with abiraterone. The approved niclosamide formulation has poor oral bioavailability. The primar
Externí odkaz:
https://doaj.org/article/7deaebe005d14169a2841537a9f695b8
Autor:
Demin Cai, Junjian Wang, Bei Gao, Jin Li, Feng Wu, June X. Zou, Jianzhen Xu, Yuqian Jiang, Hongye Zou, Zenghong Huang, Alexander D. Borowsky, Richard J. Bold, Primo N. Lara, Jian Jian Li, Xinbin Chen, Kit S. Lam, Ka-Fai To, Hsing-Jien Kung, Oliver Fiehn, Ruqian Zhao, Ronald M. Evans, Hong-Wu Chen
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-17 (2019)
Enhanced cholesterol biosynthesis is associated with cancer progression. Here the authors identify the nuclear receptor RORγ as a novel master regulator of cholesterol metabolism in triple negative breast cancer (TNBC) and find that RORγ small-mole
Externí odkaz:
https://doaj.org/article/985e83249405455e850f73d41a842e97
Autor:
Joseph M. Unger, Katherine Griffin, Gary W. Donaldson, Karen M. Baranowski, Margorie J. Good, Eunicia Reburiano, Maha Hussain, Paul J. Monk, Peter J. Van Veldhuizen, Michael A. Carducci, Celestia S. Higano, Primo N. Lara, Catherine M. Tangen, David I. Quinn, James L. Wade, III, Nicholas J. Vogelzang, Ian M. Thompson, Jr, Carol M. Moinpour
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-10 (2018)
Abstract Background SWOG S0421 was a large randomized trial comparing docetaxel/prednisone plus placebo (DPP) to docetaxel/prednisone plus atrasentan over 12 cycles for patients with metastatic castration-resistant prostate cancer (mCRPC). The curren
Externí odkaz:
https://doaj.org/article/b886bdc66c744576bec9567dfc8ec7ee